Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy

  • Li, Xiao-Xia (Intensive Care Unit, Zhumadian Central Hospital) ;
  • Zhang, Yong-Gang (Intensive Care Unit, Zhumadian Central Hospital) ;
  • Wang, Dong (Intensive Care Unit, Zhumadian Central Hospital) ;
  • Chen, Yun-Fang (Department of Oncology, Zhumadian Central Hospital) ;
  • Shan, Yan-Hua (Intensive Care Unit, Zhumadian Central Hospital)
  • Published : 2015.07.13


Objective: To explore the preventive effect of aspirin on the cardiovascular complications in prostate cancer after endocrinotherapy. Materials and Methods: A total of 92 patients with prostate cancer were divided into observation group (n=44) and control group (n=48). The control group was treated with medical castration plus anti-androgenic drugs. Based on the above treatment, the observation group was added aspirin. The follow-up duration was 2 years. The changes of partial prothrombin time (PT), activated partial thromboplastin time (APTT), platelet aggregation rate (PAG), prostate-specific antigen (PSA) and serum testosterone (T) before and after treatment as well as incidence of cardiovascular disease were observed. Results: The 2-year survival rates of patients without cardiovascular disease in observation group and control group were 95.45% (42/44) and 72.92% (35/48), respectively, and significant difference was presented between two groups by comparison to the survival rates ($x^2=8.5453$, p=0.0035). There was no statistical significance between two groups as well as before and after treatment regarding PT (p>0.05). After treatment, APTT went down and PAG was gradually on the rise in control group, while PAG down and APTT on the rise increasingly in observation group. Significant differences were presented between two groups as well as before and after treatment (p<0.01). Both PSA and T levels were decreased significantly in two groups after treatment (p<0.01), but there was no statistical significant between two groups (p>0.05). Conclusions: Application of endocrinotherapy in prostate cancer can easily lead to occurrence of cardiovascular disease, but cardiovascular complications can be prevented by aspirin, without affecting the effect of endocrinotherapy.


Prostate cancer;endocrinotherapy;cardiovascular disease;side effects;aspirin


  1. Atoum MF, AlKateeb D, AlHaj Mahmoud SA (2015). The Fok1 vitamin D receptor gene polymorphism and 25 (OH) D serum levels and prostate cancer amongJordanian men. Asian Pac J Cancer Prev, 16, 2227-30.
  2. Al-Khazaali A, Arora R, Muttar S (2015). Controversial effects of exogenous testosterone on cardiovascular diseases. Am J Ther, PMID: 25719442.
  3. Battistoni A, Mastromarino V, Volpe M (2015). Reducing cardiovascular and cancer risk: how to address global primary prevention in clinical practice. Clin Cardiol, doi: 10.1002/clc.22394.
  4. Daniyal M, Siddiqui ZA, Akram M, et al (2014). Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev, 15, 9575-8.
  5. Esfahani M, Ataei N, Panjehpour M (2015). Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev, 16, 2601-11.
  6. Glueck CJ, Wang P (2014). Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism, 63, 989-94.
  7. Krahn M, Bremner KE, Tomlinson G, et al (2011). Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int, 108, 1588-96.
  8. Prabhat P, Tewari R, Natu SM, et al (2010). Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian J Urol, 26, 502-6.
  9. Park TE, Yusuff J, Sharma R, et al (2015). Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. Int J STD AIDS, doi: 10.1177/0956462415585448.
  10. Rosano GM, Vitale C, Fini M (2015). Testosterone in men with hypogonadism and high cardiovascular risk. Pros Endocrine, doi: 10.1007/s12020-015-0561-6.
  11. Saad F (2012). Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev, 28, 52-9.
  12. Schror K (2015). Why we should not skip aspirin in cardiovascular prevention. Hamostaseologie, 35, doi:
  13. Thomsen FB, Brasso K, Christensen IJ, et al (2015). Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. Eur J Cancer, doi: 10.1016/j.ejca.2015.03.021.
  14. Teoh JY, Chiu PK, Chan SY, et al (2015). Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol, 45, 483-7.
  15. Van Poznak CH (2015). Bone Health in Adults Treated with Endocrine Therapy for Early Breast or Prostate Cancer. Am Soc Clin Oncol Educ Book, 35, e567-74.
  16. Vaidya D, Golden SH, Haq N, et al (2015). Association of sex hormones with carotid artery distensibility in men and postmenopausal women: multi-ethnic study of atherosclerosis. Hypertension, 65, 1020-5.
  17. Williams CD, Chan AT, Elman MR, et al (2015). Aspirin use among adults in the u.s.: results of a national survey. Am J Prev Med, 48, 501-8.

Cited by

  1. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer vol.14, pp.10, 2018,